QURE250117C12000
- 3.33
- -0.67-16.75%
uniQure NV Newsroom
Is UniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025?
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
UniQure Prices Public Offering Of 4.41M Of Its Ordinary Shares At $17.00 Per Share
UniQure Files Mixed Shelf; Shares Fall After Hours
UniQure Announces Proposed Public Offering; No Size Or Amount Disclosed
RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $24
RBC Raises Price Target on UniQure to $24 From $20, Keeps Outperform, Speculative Risk
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Mizuho Securities Maintains UniQure NV(QURE.US) With Hold Rating, Maintains Target Price $20
Express News | Uniqure NV : Mizuho Raises Target Price to $20 From $7
Mizuho Securities Maintains UniQure NV(QURE.US) With Hold Rating, Announces Target Price $20
UniQure Is Maintained at Buy by Stifel
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $32
Notable Analyst Calls This Week: AMD, Adobe and Utilities Stocks Among Top Picks
Uniqure Insider Sold Shares Worth $1,503,000, According to a Recent SEC Filing
UniQure Is Maintained at Neutral by Goldman Sachs
Guggenheim Reiterates Buy on UniQureto Buy
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Raises Target Price to $20
UniQure Is Maintained at Outperform by RBC Capital
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug